Standard of Care sensibility: Rituximab = yes (30mg/kg) / Endoxan = yes ( 100mg/kg) / Obinutuzumab = yes (30mg/kg) / R-CHOP or R-DHAP = yes
Acquired resistance to: Rituximab / GA101 / R-CHOP / R-DHAP
RL cells
Human RL cells were isolated from the ascite of a patient with non-hogkin’s follicular lymphoma.
Tumour growth in vivo
The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.
The mice bearing RL tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.
Figure 1: (View PDF)
Tumour growth curve of the RL cells as xenograft Mean ± SEM (n=6; take rate 100%)
Antineo can also perform an intra-medullar implantation.
Standard-Of-Care Drug Responses
rituximab 30 mg/kg qw → Response
endoxan 100 mg/kg qw → Response
Figure 2: View PDF
Effect of rituximab or endoxan treatment on RL tumour growth
Mean ± SEM (n=6 per group; take rate 100%)
obinutuzumab 30 mg/kg qw → Response
R-CHOP or R-DHAP → Response
Several RL resistant models, developed in vivo without
genetic modifications, are available at Antineo (model ID RL rituxR); RL GA101R; RL RCHOPR, RL RDHAPR).